TapImmune today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.
TapImmune today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City.
TapImmune today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018, at the Waldorf Astoria Chicago Hotel.
TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform
TapImmune Inc. (NASDAQ: TPIV) announced today that Peter Hoang, President and CEO, will host a video webinar and slide presentation to discuss the details of the proposed merger with Marker Therapeutics, Inc., on Thursday, May 24, 2018, at 4:05 p.m. EST. The webinar will be followed by a live Q&A session.
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
TapImmune today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company’s transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments
TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.
TapImmune today provided its first quarterly business update, following the company’s uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer
TapImmune announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).